Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCAGN02390 · 1 trial · 21 indications
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.
PAD defined as a dose that achieves a level of receptor occupancy considered to be biologically active.
| Arm | Type | Description |
|---|---|---|
| INCAGN02390 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| INCAGN02390 | DRUG | Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD. |
Inclusion Criteria: * Participants with locally advanced or metastatic tumors who are not eligible for any available therapy likely to convey clinical benefit (locally advanced disease must not be amenable to resection with curative intent). * Participants who have disease progression after treatme...
Top 20 of 26 competitors
INCAGN02390 is an investigational small molecule being studied for the treatment of cervical cancer. It is currently in Phase 1 clinical development and is not yet approved by the FDA. The drug is being evaluated for safety and tolerability in patients with select advanced malignancies, including cervical cancer.
INCAGN02390 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY. The company is conducting clinical trials to evaluate the drug's safety and tolerability in patients with advanced malignancies.
INCAGN02390 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. A Phase 1 trial has been completed to assess its safety and tolerability in patients with select advanced malignancies, including cervical cancer.
INCAGN02390 has one completed clinical trial, identified as NCT03652077. This Phase 1 study evaluated the safety and tolerability of INCAGN02390 in select advanced malignancies, including cervical cancer, and enrolled 40 participants in the United States.
INCAGN02390 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A Phase 1 trial has been completed to evaluate its safety and tolerability, but the drug has not yet been approved for any indication.